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SUMMARY 
mTOR complex 1 (mTORC1) is central to the control of cell, organ and organismal 
size. Skeletal muscle-specific inactivation of mTORC1 in mice results in smaller 
muscle fibers, fewer mitochondria, increased glycogen stores and a progressive 
myopathy that causes premature death. Interestingly, PGC-1α, which regulates 
mitochondrial biogenesis and glucose homeostasis, was strongly downregulated. 
Here we tested whether activation of PGC-1α is sufficient to reverse the phenotype in 
the mTORC1-inactive mice using a genetic and a pharmacological approach. We 
show that both paradigms improve mitochondrial function but do not affect the 
progressive myopathy. In addition, we find that the mTORC1 pathway is dominant 
over PGC-1α in determining the amount of glycogen stored. Thus, our work provides 
strong functional evidence that mitochondrial dysfunction in mice with inactivated 
mTORC1-signaling is due to downregulation of PGC-1α. Importantly, this 
downregulation does not cause the lethal myopathy and glycogen increase. 
 
 
 
 
 
 
 
 
 
Highlights: raptor, PGC-1α, mTOR, bezafibrate,  
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INTRODUCTION 
Adaptations of skeletal muscle to changes in the environment have been shown to 
depend on insulin-like growth factor (IGF); protein kinase B (PKB)/Akt and 
mammalian target of rapamycin (mTOR) signaling (Glass, 2005). mTOR is a highly 
conserved protein kinase that is best known for its central role in the control of cell 
size through the regulation of protein synthesis (Wullschleger et al., 2006). It is found 
in two distinct multiprotein complexes, called mTOR complex 1 (mTORC1) and 
mTORC2. Mice with muscle-specific deletion of mTOR or raptor, an essential 
component of mTORC1, suffer from a progressive muscle myopathy that causes 
premature death at the age between four and six months (Bentzinger et al., 2008; 
Risson et al., 2009). Importantly, muscles of mTOR- (mTOR muscle knockout) and 
RAmKO (raptor muscle knockout) mice showed impaired mitochondrial function and 
an increase in glycogen. The mitochondrial phenotype correlated with the strong 
reduction of peroxisome proliferator activated receptor-γ (PPARγ) coactivator α 
(PGC-1α), which regulates mitochondrial biogenesis and glucose homeostasis in 
skeletal muscle (Wende et al., 2007; Wu et al., 1999) and has been shown to 
associate with mTOR (Cunningham et al., 2007). Interestingly, like in RAmKO and 
mTOR- mice, muscle-specific inactivation of PGC-1α resulted in a myopathy leading 
to muscle damage and regeneration (Handschin et al., 2007a) and overexpression of 
PGC-1α in mdx mice, a mouse model of Duchenne muscular dystrophy, was shown 
to ameliorate the disease phenotype (Handschin et al., 2007b). These data suggest 
that both, the metabolic (mitochondria and glycogen content) and the myopathic 
phenotype, of mTOR- and RAmKO mice could be based on the deregulation of PGC-
1α expression.  
 In the current study, we tested this question by transgenic overexpression of 
PGC-1α in RAmKO mice and by pharmacological activation of PGC-1α by 
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bezafibrate, a PPAR pan-agonist (Wenz et al., 2008) in mTOR- mice. We find that 
both treatments improve mitochondrial function but that they do not affect the 
progressive muscle myopathy. In addition, we find that the increase in glycogen in 
mTOR- and RAmKO mice is predominated by the activation of PKB/Akt and not by 
changes in PGC-1α. Thus, while mitochondrial changes in mTOR- and RAmKO mice 
are functionally linked to the decreased levels of PGC-1α, both the progressive 
myopathy and the increase in glycogen are not directly associated with those 
changes.  
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RESULTS 
 
Transgenic overexpression of PGC-1α restores mitochondrial function in 
RAmKO mice 
One of the most striking phenotypes of RAmKO and mTOR- mice is the decrease in 
oxidative capacity and the morphological changes in the mitochondria (Bentzinger et 
al., 2008; Risson et al., 2009). In both mouse models, this correlated with a decrease 
in the transcript levels of PGC-1α, which led to the hypothesis that the mitochondrial 
phenotype was due a direct effect of mTORC1 on the expression of PGC-1α, as had 
been suggested earlier (Cunningham et al., 2007). To test this hypothesis, we 
therefore crossed RAmKO mice with mice that overexpress PGC-1α in skeletal 
muscle using the muscle creatine kinase (MCK) promoter (Lin et al., 2002). The 
resulting RAmKO mice that were also transgenic for PGC-1α (called herein RAmKO-
PGC1α-TG) expressed increased levels of PGC-1α in both fast- (Extensor digitorum 
longus (EDL), Figure 1A) and slow- twitch (soleus, Figure S1A available online) 
muscles, despite the reduced amount of raptor as shown by Western blot analysis 
(Figure S1B available online). To evaluate the effect of PGC-1α on mitochondria 
number, we used quantitative real-time PCR (qRT-PCR) to determine the copy 
number of mtDNA (D-loop region) relative to the amount of genomic DNA (using 
sequences for the gene Ndufv1) (Amthor et al., 2007). These data showed that 
RAmKO mice have a reduced number of mitochondria (Figure 1B), consistent with 
their low oxidative capacity. The reduction of mitochondria was restored to wild-type 
levels in RAmKO-PGC1α-TG mice, although the mitochondria level was still lower 
than in the PGC1-TG mice (Figure 1B). The same trend was seen for transcript 
encoding mitochondrial proteins, including medium-chain acyl dehydrogenase 
(MCAD), cytochrome c, cytochrome c oxidase (COX IV), and citrate synthase (Figure 
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1C), which are all known targets of PGC-1α (Wu et al., 1999). These data thus show 
that PGC-1α is functional in the RAmKO-PGC1α-TG mice. This was also confirmed 
by the NADH-tetrazolium (NADH-TR) staining of skeletal muscle as the low oxidative 
capacity is reversed to at least control levels in RAmKO-PGC1α-TG mice (Figure 
1D). The improvement of mitochondria by the overexpression of PGC-1α was also 
obvious in electron micrographs, which clearly indicate the restoration of both the 
shape and the number of mitochondria in RAmKO-PGC1α-TG mice. In fact, the size 
of the mitochondria was increased compared to control like those in muscle from 
mice transgenic for PGC-1α (Figure 1E; Wende et al., 2007; Wenz et al., 2008). 
 
The mTORC1 and PKB/Akt predominate over PGC-1 on the regulation of 
glycogen in skeletal muscle 
Recent evidence has implicated PGC-1α in the regulation of glucose metabolism in 
muscle (Wende et al., 2007). As RAmKO and mTOR- mice had an approximately 5-
fold increase in glycogen in skeletal muscle (Bentzinger et al., 2008; Risson et al., 
2009), we also investigated whether PGC-1α expression would affect this parameter. 
To examine this, we stained muscle cross-sections with periodic acid-Schiff (PAS) 
and quantified the amount of glycogen by an enzymatic assay. As described before 
(Bentzinger et al., 2008; Wende et al., 2007), the glycogen content was increased in 
RAmKO and PGC1α-TG mice (Figure 2A and B). The increase in glycogen was 
much more pronounced in the RAmKO mice than in PGC1α-TG mice. Interestingly, 
the effect of PGC-1α and raptor deletion was additive (RAmKO-PGC1α-TG mice; 
Figure 2 A and B), suggesting that the two factors affect independent signaling 
pathways. One mechanism responsible for the stronger increase of glycogen in 
RAmKO mice is very likely due to the hyperactivation of PKB/Akt seen by the 
hyperphosphorylation of the T308 and S473 site of PKB/Akt (Figure 2C, Table 1 
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available online). An additional observation we made is that the total amount of 
PKB/Akt is increased when PGC-1 levels are increased (Figure 2C, Table 1 
available online). This nevertheless does not seem to have an effect on both 
phosphorylations of PKB/Akt, as those are unchanged when one compares the 
raptor-deleted mice with the other two mouse models.  
 A well described target of PKB/Akt is the glycogen synthase kinase 3 (GSK3), 
which inhibits the glycogen synthase (Sakamoto and Goodyear, 2002). This protein 
again was hyperphosphorylated (Figure 2C, Table 1 available online) indicating a 
higher synthesis of glycogen in the skeletal muscles. The mechanism suggested for 
the milder increase of glycogen in the PGC1α-TG mice is the downregulation of the 
glycogen phosphorylase (Wende et al., 2007). This downregulation can be observed 
in these mice both on the mRNA (Figure 2D) as well as on the protein level (Figure 
2C, Table 1 available online). What is striking is that the same could be observed in 
the two other mouse models. RAmKO mice and PGC1α-TG mice have very different 
levels of PGC-1α, but in both mouse models the glycogen phosphorylase is down to 
the same extent.  
 
Increase in PGC-1α expression does not prevent muscle dystrophy in mice 
with inactive mTORC1 
When PGC-1α levels are maintained transgenically, the loss of muscle mass after 
denervation is reduced and muscle fiber volume is maintained (Sandri et al., 2006). 
One of the main features of the RAmKO mice was muscle atrophy and a progressive 
muscle dystrophy resulting in their premature death. Thus an amelioration of the 
dystrophic phenotype could be expected in the RAmKO-PGC1α mice. Nevertheless 
when weighing the muscles of 140-day old mice of all our mouse models the 
reduction of skeletal muscles could still be observed in the RAmKO-PGC1α-TG mice 
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(Table 2 available online) just as the significant reduction of the whole body weight 
after 60 days of age (Figure 3A). At an age of 90 days the RAmKO-PGC1-TG mice 
showed several signs of a muscle dystrophy in a hematoxylin eosin (H&E) staining of 
cross-sections (Figure 3B). The mice showed a high number of very small fibers 
(blue arrows), resulting in an alteration of the muscle size distribution (Figure 3C). 
Additionally mononuclear cells were found (green arrows), as were centralized nuclei 
in several muscle fibers (white arrows in Figure 3B and quantification in Figure D). 
This severe myopathy resulted in a reduced activity of the RAmKO mice that was not 
significantly changed upon the increase of PGC-1α levels (Figure E). Additionally the 
mice developed a severe kyphosis after around 20 weeks (Figure 3F and G) and died 
prematurely (data not shown), again known signs of muscle dystrophy already 
described in the RAmKO mice (Bentzinger et al., 2008). These results point out that 
the increase of PGC-1α, although beneficial for the mitochondrial function and 
number is not sufficient to rescue the dystrophic phenotype of RAmKO mice. 
 
Bezafibrate partially restores mitochondria function in muscles in the absence 
of mTOR and does not affect the muscle dystrophy 
We could show that in mTORC1-inactivated muscles the mitochondrial but not the 
dystrophic phenotype could be rescued through a genetic increase of PGC-1α. Next 
we decided to test if a pharmacological approach would show the same results. For 
this we used bezafibrate, a PPAR pan-agonist that activates the PPARs/ PGC-1α 
pathway (Bastin et al., 2008; Tenenbaum et al., 2005). Administration of bezafibrate 
increases PGC-1α expression and its best described targets in skeletal muscle and 
was shown to improve a mitochondrial myopathy phenotype (Wenz et al., 2008). To 
see if our observations are consistent in different mouse models, we used mice with 
a skeletal muscle-specific ablation of mTOR (called mTOR-), which show a very 
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similar phenotype as the RAmKO mice. The mitochondrial function is reduced and 
the mice suffer from a progressive muscle dystrophy that is more pronounced than 
the RAmKO mice (Risson et al., 2009). The mTOR- mice were fed a diet containing 
0.5% bezafibrate for 20 weeks starting at 5 weeks of age. qRT-PCR analysis showed 
that bezafibrate treatment significantly increased expression of PGC-1αand several 
mitochondrial proteins (Figure 4A). In addition, bezafibrate partially restored the 
activity of oxidative enzymes as shown by staining muscle cross sections for 
succinate dehydrogenase- (SDH) and cytochrome oxidase (COX) (Figure 4B; Figure 
S2B available online). Significantly increased oxidative capacity of mTOR- muscles 
was further confirmed by measuring SDH activity directly (Figure 4C).  
 We next addressed if improved mitochondrial function would ameliorate the 
muscle dystrophy in the mTOR- mice. H&E staining of muscle cross sections showed 
that the signs of muscle dystrophy are still present after the bezafibrate treatment 
(Figure 4D). In addition, cycles of muscle de- and regeneration were still increased as 
shown by the increased levels of perinatal muscle myosin heavy chain (MHC) MyH8 
and myogenin. Also the levels of dystrophin, which are reduced in mTOR- mice 
(Risson et al., 2009), were not affected by bezafibrate (Figure 4E). Moreover, muscle 
mass was reduced (Table 3 available online), bezafibrate-treated mTOR- mice 
develop a kyphosis (Figure S2A available online) and still died around the same age 
as untreated mice (data not shown). Finally, bezafibrate did not improve specific 
force production, as the tetanic force (Po) was still reduced in both fast- (tibialis 
anterioris) and slow- twitch (soleus) muscles of mTOR- mice (Table 3 available 
online).  
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DISCUSSION  
This work provides direct functional evidence that the mitochondrial deficits in mTOR- 
and RAmKO mice are the consequence of decreased expression of PGC-1α. 
Furthermore, our study shows that both the high glycogen content and the severe 
myopathy observed in mTORC1-deficient mice cannot be reversed by changing 
PGC-1α function. We chose to examine this question by using (1) mice transgenic for 
PGC-1α (Lin et al., 2002), where the transgene is driven by the MCK promoter that is 
mainly expressed in fast-twitch muscle fibers and (2) bezafibrate which reaches all 
muscles. Also, bezafibrate is used in clinical trials and was successfully used in the 
cox10 mouse model to delay the onset of the mitochondrial myopathy (Wenz et al., 
2008). The rescue in mitochondrial number and function is based on the 
normalization of the mtDNA content, of the levels of key mitochondrial enzymes and 
of the oxidative capacity. Despite the normalization of the oxidative capacity in 
RAmKO-PGC1α-TG mice, overall running activity was still much lower than in control 
mice. This clearly suggests that it is rather the myopathic than the metabolic changes 
in RAmKO muscle that prevent the mice to run as far as control littermates. 
 The mechanism by which mTORC1 influences expression of PGC-1α and 
therefore mitochondrial biogenesis is the formation of a complex of mTORC1, PGC-
1α and the transcription factor yin-yang 1 (YY1; Cunningham et al., 2007). 
Surprisingly, our data now show that the function of PGC-1α to drive mitochondrial 
biogenesis does not require mTORC1. However, we noted that the expression levels 
of PGC-1α and its downstream targets, such as MCAD and cytochrome C, were 
consistently lower in RAmKO-PGC1α-TG than in PGC1α-TG mice. An additional 
reason for the lower levels of PGC-1α could the increased activity of PKB/Akt in the 
RAmKO-PGC1α-TG mice. Activated PKB/Akt was shown to directly inhibit PGC-1α 
by phosphorylation (Li et al., Nature 2007).  
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 We also observed that the genetically modified muscles all contained a 2 to 15-
fold increase in glycogen. Our findings that PGC-1α-TG and RAmKO-PGC-1α-TG 
mice have increased levels of glycogen compared to their respective littermate 
controls, is in agreement with the finding, that PGC-1α inhibits transcription of 
glycogen phosphorylase (Wende et al., 2007). However, the increase in glycogen 
was much more pronounced in those mice deficient for raptor, suggesting that 
glycogen content is predominantly determined by the activity of mTORC1 and not by 
PGC-1α. Moreover, in the RAmKO mice, glycogen phosphorylase levels are low 
despite the low levels of PGC-1α. We hypothesize that this effect on glycogen 
phosphorylase is due to the strong hyperactivation of PKB/Akt, as was seen in 
hepatocytes (Aiston et al., 2006). In addition, activated PKB/Akt regulates glycogen 
synthase via GSK3 (Sakamoto and Goodyear, 2002). Thus, the change in both 
enzymes is probably responsible for the pronounced increase in glycogen in the 
raptor-deficient mice.  
 Finally, our data also show that increased levels of PGC-1α and improved 
mitochondrial function is not sufficient to reverse any aspects, such as fibrosis, 
atrophy, centralized nuclei of the severe myopathy in mTORC1-deficient mice. Most 
importantly, disease onset was not altered at all by the overexpression of PGC-1α or 
the administration of bezafibrate. We could not observe a beneficial effect of PGC-1α 
overexpression on muscle mass in the slightly atrophic RAmKO muscle although it 
has been reported that PGC-1α can counteract denervation-induced atrophy and 
age-related muscle loss (Sandri et al. 2006; Wenz et al. 2009). 
 The exact molecular mechanisms responsible for the lethal myopathic phenotype 
in RAmKO and mTOR- mice remain open. Circumstantial data indicate that the 
accumulation of glycogen is unlikely the cause. For example, mice overexpressing a 
hyperactive form of glycogen synthase, which results in a more than 20-fold higher 
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concentrations of glycogen do not display any muscular dystrophy or change in 
exercise performance (Pederson et al., 2005).  
 The most likely scenario is that alteration in the balance between protein 
synthesis and protein degradation is responsible. Changes in this balance affect 
proteasomal and autophagic protein degradation and overall protein synthesis. 
Recent evidence indeed shows that such a shift in the balance results in dystrophic 
phenotypes, be it via the inactivation of autophagy (Masiero et al., 2009), the 
proteasome pathway and hyperactivation of PKB/Akt (Grumati et al., 2010). Thus, a 
change in the balance between protein synthesis and degradation as observed in 
RAmKO and mTOR- mice is likely to affect the health of skeletal muscle.  
 In summary, our data show that the mTORC1 regulates mitochondrial activity 
through PGC-1αand is also the main regulator of glycogen in skeletal muscle. Plus 
the muscle dystrophy seen after the inactivation of mTORC1 is not dependent on 
mitochondrial activity and the PGC-1αpathway. 
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EXPERIMENTAL PROCEDURES 
 
Animals 
RAmKO, mTOR- and PGC1-TG mice were described earlier (Bentzinger et al., 
2008; Lin et al., 2002; Risson et al., 2009). The RAmKO-PGC1-TG mice were 
generated by crossing the RAmKO with the PGC1-TG mice. Mice were maintained 
in a conventional facility with a fixed light cycle. Body weight was measured weekly. 
Studies were carried out according to criteria outlined for the care and use of 
laboratory animals and with approval of the Swiss (for experiments with RAmKO, 
PGC1-TG and RAmKO-PGC1-TG mice) and French authorities (for experiments 
with mTOR- mice), respectively. 
 
Quantitative Real-time PCR 
Total RNA was isolated (SV Total RNA isolation System, Promega) and equal 
amounts of RNA reverse transcribed using a mixture of oligodT and random hexamer 
primers (iScript cDNA Synthesis Kit, Bio-Rad). Quantitative real-time PCR (qRT-
PCR) was performed using SYBR Green (Power SYBR Green Master Mix, Applied 
Biosystems) and StepOneTM Software 2.1. (Applied Biosystems). Expression levels 
for each gene of interest were normalized to the mean cycle number using qRT-PCR 
for the housekeeping protein β-actin. 
 
Quantification of mtDNA Copy Numbers 
Total DNA was extracted and purified with a standard chloroform/ethanol 
precipitation after proteinase K digestion. DNA concentrations were determined 
photometrically, adjusted to 50 ng/µl and used to quantify the amount of mtDNA with 
respect to the genomic DNA by qRT-PCR. For the quantification of the mtDNA, 
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primers were used that are complementary to the D-loop region. Primers to quantify 
genomic DNA were directed against the single-copy nuclear gene Ndufv1. 
 
Histology 
Muscles frozen in liquid nitrogen-cooled isopentane were cut into 12 µm cross-
sections. General histology on cross sections was performed using hematoxylin and 
eosin (H&E, Merck). NADH staining was done as described (Dunant et al., 2003). 
Periodic acid-Schiff staining (PAS staining system, Sigma) was performed according 
to the manufacturer’s instruction. After all stainings samples were dehydrated and 
mounted with DePex mounting medium (Gurr, BDH). Succinate dehydrogenase 
(SDH) and cytochrome oxidase (COX) staining were carried out as described in 
(Konieczny et al., 2008; MacArthur et al., 2007), respectively. 
 
Statistics 
Compiled data are expressed as mean ± SD. One Way Analysis of Variance 
(ANOVA) and a priori defined contrast analysis were performed for statistical 
comparisons of the different groups. The level of significance is indicated as follows: 
***/### p<0.001, **/## p< 0.01, */# p< 0.05. 
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FIGURE LEGENDS 
 
Figure 1. Increased PGC-1 levels normalize mitochondrial properties in 
RAmKO mice. 
(A) Relative mRNA levels of PGC-1in EDL muscle of 90-day-old mice as 
determined by qRT-PCR (n≥3 mice). 
(B) Mitochondrial DNA content in EDL muscle of 140-day-old mice. The amount of 
mtDNA was quantified by qRT-PCR and expressed relative to the amount of nuclear 
DNA (n≥2 mice). 
(C) Relative mRNA levels of the indicated proteins in EDL muscle of 90-day-old mice 
as determined by qRT-PCR (n≥3 mice). * transgenic mice compared to ctrl mice, # 
transgenic mice compared to RAmKO mice. 
(D) Activity of oxidative enzymes examined by NADH-tetrazolium staining (blue 
precipitate) in TA muscle of 130-day-old mice. Scale bar = 100µm 
(E) Electron micrographs of longitudinal sections of EDL muscle of 140-day-old mice. 
Scale bar = 200nm.  
Individual data points and bars (A, B and C) represent means ± SD. p values are 
*/#p<0.05, **/##p<0.01, ***/###p<0.001. 
 
Figure 2. The glycogen content is increased in all mouse models. 
(A) Periodic acid-Schiff (PAS) staining of cross-sections of TA muscle of 90-day-old 
mice. The reaction product (magenta color) is indicative of amount of glycogen in the 
tissue. Scale bar = 50µm 
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(B) Glycogen concentration in the TA muscle from 90-day-old mice.  
(C) Western blot analysis of EDL muscle from 80-day-old mice using antibodies 
directed against the proteins indicated. Equal amount of protein was loaded in each 
lane. An antibody against -actinin was used as loading control. 
(D) Relative mRNA levels of glycogen phosphorylasein EDL muscle of 90-day-old 
mice as determined by qRT-PCR (n≥3 mice). 
Individual data points and bars (B and D) represent means ± SD. p values are 
*p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3. Transgenic increase in PGC-1 level does not prevent muscle 
dystrophy in mice with inactive mTORC1. 
(A) Mice of each genotype were weighed every week. RAmKO and RAmKO-PGC1-
TG mice are significantly lighter after the age of 63 days. (n≥5 mice) 
(B) Hematoxylin and eosin (H&E) staining of cross-sections of TA muscle of 130-day-
old mice. In the muscle of RAmKO and RAmKO-PGC1-TG mice some large (blue 
arrows) but also small fibers are present. Both genotypes also show centralized 
nuclei (white arrows) and many mononuclear cells (green arrows). 
(C) Fiber size distribution in the TA muscle of 140-day-old mice. RAmKO and 
RAmKO-PGC1-TG mice have significantly (p<0.05) more fibers that have a fiber 
feret of 20-30µm than control littermates. The amount of fibers with a fiber feret 
between 40-50µm is significantly reduced in RAmKO mice (p=0.024) and shows a 
trend towards reduction in RAmKO-PGC1-TG mice (p=0.064). 
(D) Mean percentage of muscle fibers with centralized nuclei (cnf) in TA muscle of 
90-day-old mice. (n≥5 mice) Individual data points and bars represent means ± SD.  
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(E) Average distance run voluntarily per day determined between the age of 95 days 
and 105 days. (n≥3) Individual data points and bars represent means ± SEM.  
(F) Photographs of 140-day-old littermates. The RAmKO and RAmKO-PGC1-TG 
mice are leaner and suffer from a kyphosis.  
(G) Percentage of mice suffering from kyphosis was determined over several weeks. 
(n≥7 mice) P values (D and E) are *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 4. Bezafibrate partially restores mitochondrial function in muscles in the 
absence of mTOR, but does not affect the muscle myopathy. 
(A and E) Relative mRNA levels of the indicated proteins in soleus muscle as 
determined by qRT-PCR (n≥3 mice). Individual data points and bars represent 
means ± SEM.  
(B) Oxidative properties examined by succinate-dehydrogenase (SDH) staining in 
hind leg muscles. The soleus muscle is marked by an asterisk. Darkly stained fibers 
contain high SDH activity. Scale bar = 100µm 
(C) SDH activity in soleus muscle (n≥5 mice). Individual data points and bars 
represent means ± SD. 
(D) Hematoxylin and eosin (H&E) staining of cross-sections of soleus muscle. In the 
muscle of mTOR- and mTOR- mice treated with bezafibrate some large (blue arrows) 
but also small fibers are present. Both genotypes also show centralized nuclei (white 
arrows) and many mononuclear cells (green arrows). Scale bar = 50µm 
All mice (A-E) were male and 140 days old. p values (A, C, E) are *p<0.05, **p<0.01, 
***p<0.001. * transgenic mice compared to ctrl mice, # transgenic mice compared to 
mTOR- mice. 
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SUPPLEMENTAL DATA  
 
SUPPLEMENTAL TABLES 
 
(1) Weight or length was measured for different organs in 140-day-old mice. (n>6 
mice) * transgenic mice compared to ctrl mice, # transgenic mice compared to 
RAmKO mice. 
(2) Muscle contractile properties of 140-day-old mice were assessed by recording 
isometric forces in response to electrical stimulation. The following data were 
measured: muscle mass, absolute maximum tetanic force (Po), specific tetanic force 
(sPo), peak twitch tension (Pt), time taken for maximal twitch tension to fall by 20% 
(F20%).(n>3 mice) * mTOR- compared to ctrl mice, # mTOR- mice compared to 
mTOR- mice treated with bezafibrate.  
Values for both tables represent means ± SD. P values determined by Student’s t 
test are indicated by asterisks. P values are */#p<0.05, **/##p<0.01, ***/###p<0.001. 
 
 
SUPPLEMENTAL FIGURES 
 
(A) Relative mRNA levels of PGC-1in soleus muscle of 90-day-old mice as 
determined by qRT-PCR (n≥3 mice).Individual data points and bars represent means 
± SD. p values are *p<0.05, **p<0.01, ***p<0.001. 
(B) Raptor protein amount was determined by Western blot analysis of soleus muscle 
from 80-day-old mice. Equal amount of protein was loaded in each lane. An antibody 
against -actinin was used as loading control. 
(C) Photographs of 140-day-old littermates. 
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(D) Cytochrome oxidase (COX) staining in hind leg muscles. COX is the complex IV 
of the respiratory chain enzymes and its activity is representative for the oxidative 
enzymes. The soleus muscle is marked by an asterisk. Scale bar = 100µm 
(E) For the qRT-PCR the following primers were used: β-actin (forward: 5' CAG CTT 
CTT TGC AGC TCC TT, reverse: 5' GCA GCG ATA TCG TCA TCC A). PGC-1 
(forward: TGA TGT GAA TGA CTT GGA TAC AGA CA, reverse: GCT CAT TGT TGT 
ACT GGT TGG ATA TG), PPAR (forward: GCG TAC GGC AAT GGC TTT AT, 
reverse: ACA GAA CGG CTT CCT CAG GTT), PPAR (forward: GCA AGC CCT 
TCA GTG ACA TCA, reverse: CCA GCG CAT TGA ACT TGA CA), MCAD (forward: 
AAC ACT TAC TAT GCC TCG ATT GCA, reverse: CCA TAG CCT CCG AAA ATC 
TGA A), Cytochrome C (forward: GCA AGC ATA AGA CTG GAC CAA A, reverse: 
TTG TTG GCA TCT GTG TAA GAG AAT C), COX IV (forward: TAC TTC GGT GTG 
CCT TCG A, reverse: TGA CAT GGG CCA CAT CAG), Citrate synthase (forward: 
CAA GCA GCA ACA TGG GAA GA, reverse: GTC AGG ATC AAG AAC CGA AGT 
CT), Glycogen phosphorylase (forward: CAC TTA CCA GCT GGG CTT GGA CAT, 
reverse: AAA GCA AGC TGC CAG GCG TC), COX I (forward: GGT CAA CCA GGT 
GCA CTT TT, reverse: TGG GGC TCC GAT TAT TAG TG), LCAD (forward: ATG 
GCA AAA TAC TGG GCA TC, reverse: TCT TGC GAT CAG CTC TTT CA), 
Dystrophin (forward: TGC GCT ATC AGG AGA CAA TG, reverse: TTC TTG GCC 
ATC TCC TTC AC), myogenin (forward: CTA CAG GCC TTG CTC AGC TC, reverse: 
AGA TTG TGG GCG TCT GTA GG), MyH8 (forward: CAA GGA TGG AGG GAA 
AGT GA, reverse: GGT TCA TGG GGA AGA CTT GA). 
(F) For the quantification of mtDNA copy numbers the following primers were used: 
D-loop region (forward: GGT TCT TAC TTC AGG GCC ATC A, reverse: GAT TAG 
ACC CGT TAC CAT CGA GAT), Ndufv1 (forward: CTT CCC CAC TGG CCT CAA G, 
reverse: CCA AAA CCC AGT GAT CCA GC). 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Electron Microscopy 
Transmission electron microscopy was performed as described (Moll et al., 2001). 
 
Western blotting analysis/ Glycogen content/ Fiber size distribution 
All three procedures were performed as described earlier (Bentzinger et al., 2008). 
For Western blots following antibodies were used: Akt, Phospho-Akt (Thr308), 
Phospho-Akt (Ser473), GSK-3, Phospho-GSK-3 (Ser9) and Raptor from Cell 
Signaling, -actinin from Sigma, GP from Santa Cruz. The concentrations used were 
according to the manufacturer.  
 
Voluntary wheel running 
Mice were individually housed in cages equipped with a running wheel carrying a 
magnet. Wheel revolutions were registered by a reed sensor connected to an I-
7053D Digital-Input module (Spectra), and the revolution counters were read by a 
standard laptop computer via an I-7520 RS-485-to-RS-232 interface converter 
(Spectra). Digitalized signals were processed by the "mouse running" software 
developed by Santhera Pharmaceuticals. 
 
Physiological Studies 
Measurements of muscle contractile properties were performed as described (Risson 
et al., 2009). 
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Succinate dehydrogenase activity 
Muscle samples were homogenized directly from frozen in a stabilizing medium 
containing 50% glycerol, 20 mM phosphate buffer (pH 7.4), 5 mM -mercaptoethanol, 
0.5 mM EDTA and 0.02% BSA at a dilution of 1:50 based on wet weight. Succinate 
dehydrogenase activity was determined at 37°C in a two-step assay according to a 
method adapted from (Chi et al., 1983). In the first step fumarate accumulated from 
succinate for 60 minutes and in the second step, the fumarate produced was 
measured with fumarase and a NAD-coupled reaction with malate dehydrogenase 
and the glutamate-oxaloacetate transaminase. Fluorescence reading of NADH was 
made after completion of the reaction. Standards were processed the same way as 
the samples.  
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